INM · InMed Pharmaceuticals Inc
United States · RS rating 94 · As of 2026-11-03
| Price | 1.68 USD |
|---|---|
| 1-day change | +3.1% |
| RS rating (overall / 1M / 3M / 12M) | 94 / 96 / 89 / 43 |
| Stage | Advancing |
| Composite / Minervini / CANSLIM score | 44 / 75 / 59 |
| Industry group (rank) | Medical-Ethical Drugs (94) |
| EPS growth Q/Q | -15.9% |
| Sales growth Q/Q | -26.8% |
| Distance from 52-week high | +9.2% |
| Market cap (USD) | $2.5M |